Analysis of the Effect of the COVID-19 Pandemic on Syphilis in Susceptible Populations: Men Who Have Sex with Men, People Living with HIV, and Patients with Gestational and Congenital Syphilis-A Narrative Review.

Publication date: May 25, 2025

The COVID-19 pandemic triggered a public health crisis that significantly impacted sexually transmitted infections (STIs), particularly syphilis. However, data on syphilis incidence during the pandemic remains inconsistent globally. Key groups affected include women of reproductive age, pregnant women, individuals living with HIV, and men who have sex with men (MSM). This paper reviews available literature from databases such as PubMed, Scopus, and Google Scholar to analyse the pandemic’s influence on congenital and gestational syphilis, focusing on high-risk populations. We discuss the pandemic’s impact on the incidence of gestational and congenital syphilis, including changes in screening and treatment protocols. Additionally, we examine alterations in syphilis prevalence and testing among people living with HIV and MSM, including implications observed in blood donors. The findings underscore the consequences of impaired STI diagnostics for public health. We emphasise the need for uninterrupted access to diagnostics and treatment during public health crises. To prevent rising syphilis rates post-pandemic, it is crucial to implement robust education and accessible testing measures.

Open Access PDF

Concepts Keywords
Google blood donors
Hiv congenital syphilis
Men COVID-19
Pandemic gestational syphilis
Pregnant HIV
MSM
pandemic
PLWH
syphilis

Semantics

Type Source Name
disease MESH COVID-19 Pandemic
disease MESH Syphilis
disease MESH Congenital Syphilis
disease MESH sexually transmitted infections
drug DRUGBANK Dimethyl sulfone
disease IDO blood
disease MESH Infection
disease MESH pneumonia
disease MESH cytokine storm
disease MESH emergency
disease MESH complications
disease MESH co infection
disease MESH primary syphilis
disease MESH ulcer
disease MESH tertiary syphilis
disease MESH neurological disorders
disease MESH live births
drug DRUGBANK Tetracycline
drug DRUGBANK Doxycycline
drug DRUGBANK Ceftriaxone
drug DRUGBANK Amoxicillin
disease MESH preterm birth
disease MESH perinatal death
disease MESH hepatomegaly
disease MESH ascites
disease MESH hydrops
disease MESH rhinitis
disease MESH jaundice
disease MESH keratitis
disease MESH deafness
disease IDO assay
drug DRUGBANK Flutamide
disease MESH seroconversion
disease MESH secondary syphilis
disease IDO history
drug DRUGBANK Etoperidone
drug DRUGBANK Methionine
disease MESH AIDS
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH chronic illness
disease MESH viral load
disease MESH hepatitis
disease MESH communicable diseases
disease MESH education levels
disease MESH viral infections
disease IDO susceptibility
disease MESH erythema multiforme
disease MESH trichomoniasis
disease IDO facility
drug DRUGBANK Coenzyme M
disease IDO immunodeficiency
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Lifestyle
disease MESH Gonorrhea
drug DRUGBANK Bismuth subgallate
drug DRUGBANK Abacavir
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Efavirenz
disease IDO algorithm
disease IDO intervention

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *